Publication
Biomarker-Oriented Contextual Analysis of First-Line Zolbetuximab and Immunotherapy-Based Strategies in HER2-Negative Metastatic Gastric Cancer.
Arianna Sabatini, Elisabetta Bengala, Vincenzo Picone
OncologySep 9, 2026PMID 42715128doi:10.1159/ocl/aebag012 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260915-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Purpose In HER2-negative metastatic gastric cancer, immune checkpoint inhibitors (ICIs) and CLDN18.2-targeted antibody zolbetuximab, combined with chemotherapy (CT), have emerged as first line options. Treatment selection is relatively straightforward in microsatellite instability-high (MSI-H),…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Gastric Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.